Background
The tumor suppressor gene
TP53 encodes the p53 transcription factor, which regulates target genes in multiple pathways to counteract the expansion of malignant cells [
1‐
3]. p53 thereby poses a major barrier to tumor development, explaining why tumorigenesis strongly selects for cells with inactivated p53 [
3]. Loss of p53 function (LOF) can result from p53 degradation or sequestration by viral oncoproteins or cellular inhibitors like Mdm2 or Mdmx [
4,
5]. In approximately 50% of all tumors, LOF is caused by somatically acquired genetic alterations affecting the
TP53 gene directly [
5]. This includes large deletions encompassing the entire gene as well as small non-sense, frameshift or missense mutations, which can differ massively in their functional impact [
5,
6]. Different from other tumor suppressor genes, most
TP53 mutations are missense mutations, explained in part by dominant-negative and tumor-promoting neomorphic (gain-of-function, GOF) properties of at least some of the mutant proteins [
7‐
10]. Of note, full p53 activity is essential for optimal tumor suppression as even a partial loss of p53 function increases the cancer risk in mice and causes hereditary cancer susceptibility in humans [
11‐
17].
Importantly, restoration of p53 in p53-deficient tumor cells was found to be detrimental, usually resulting in cell death or loss of proliferative capacity due to senescence or differentiation [
18]. For example, in p53ER
TAM mice with tamoxifen-switchable p53 activity, EμMyc-driven Burkitt-like lymphomas develop in the p53-off state, but undergo rapid regression when p53 is switched on [
19]. This was observed even when p53 inactivation was not the tumor-initiating driver lesion and acquired only later during tumor progression [
20]. Together with other studies in independent mouse cancer models, this firmly established that tumor cells can become addicted to the loss of p53 [
21‐
24]. Moreover, these studies demonstrated the therapeutic potential of p53 reactivation and provided critical support for the development of p53-reactivating drugs as cancer therapeutics [
25,
26].
Meanwhile a growing number of p53 reactivating compounds has been developed. While Mdm2 and Mdmx inhibitors are being evaluated for treatment of tumors with wild-type p53, diverse strategies have been proposed to target tumors with
TP53 mutations [
25,
26]. As straightforward as reactivation may seem, as challenging it turns out in practice. The most common
TP53 mutations either destroy DNA contact residues or destabilize the thermodynamically labile p53 DNA binding domain and cause its denaturation at normal body temperature [
27]. The most direct reactivation approaches aim to refold the pool of mutant p53 proteins, that have accumulated in the tumor cells, into a native conformation [
28,
29]. However, as more than 2000 different mutant proteins have been identified in cancer patients, a universal reactivation strategy is unrealistic. As such, many reactivation compounds target only single or groups of mutants [
30]. For example, PhiKan083 specifically targets a surface crevice created by the Y220C mutation [
31]. Metallochaperones increase the intracellular availability of zinc to rescue folding of zinc-binding site mutants like R175H [
32]. Arsenic trioxide (ATO) binds to a cryptic allosteric site formed by Arsenic-coordinating cysteines and stabilizes the native fold of a subset of p53 mutants [
33]. The clinically most advanced compound APR-246 (PRIMA-1
Met, Eprenetapopt), is converted to the thiol-reactive metabolite methylene quinuclidinone (MQ) and proposed to alkylate and thereby reactivate structural mutants, but also, in a mechanistically poorly understood manner, some DNA contact mutants [
34‐
36]. In combination with azacytidine, APR-246 showed promising therapeutic responses in phase II studies involving myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients [
37,
38]. However, MQ also reacts with numerous other cellular cysteines, forming a thiol-bound drug reservoir, and through depletion of glutathione (GSH) and inhibition of the GSH and thioredoxin antioxidant systems exhibits cytotoxic activities [
39,
40]. Other reactivating compounds also display considerable p53-independent toxicity that certainly adds to, if not determines, the therapeutic effects [
30]. This raises the critical question: how much of the observed cytotoxicity is due to p53 reactivation [
18]? Last but not least, the mutant p53 refolding activity of various reactivating compounds differs by at least two orders of magnitude not only between compounds but also between individual mutants [
33]. Together these findings indicate that pharmacological mutant p53 reactivation is continuously improving, but is currently still far from optimal. This brings up an even more important question: to what extent does p53 have to be restored [
18]? Is full reactivation required to achieve a therapeutic response or is partial reactivation already sufficient?
Here, we have modelled partial p53 reactivation using a conditional knock-in mouse with inducible expression of the partial LOF variant p53
E177R (short: E177R), which corresponds to human E180R. The E177R mutation disrupts an intermolecular salt-bridge with R178 (human R181) that is required for cooperative DNA binding [
41‐
43]. The decrease in cooperativity reduces DNA binding and target gene activation [
15,
44,
45]. As a result, E177R causes cancer susceptibility and cooperates with various oncogenes to promote cancer development, including lung and pancreatic adenocarcinoma and various types of leukemia and lymphoma [
15,
43,
46,
47]. Here, we report that in p53-deficient leukemia and lymphoma models the effects of E177R expression are entirely opposite: E177R inhibits cell proliferation and viability and induces cancer regression. p53-deficient cancer cells prove to be so addicted to the absence of p53 that the residual activity of E177R is detrimental for cancer growth. As such, the study provides genetic proof-of-concept that incomplete p53 reactivation can make a therapeutic impact.
Materials and methods
Animal experiments
All mouse experiments were performed according to the German Animal Welfare Law (TierSchG) and were approved by the local authorities. Mice were housed in open cages, on a 12 h light/dark cycle, fed a standard housing/breeding diet (Altromin) and received water ad libitum. The following mouse strains were used: B6.129S/Sv-Trp53tm1Thst (
Trp53LSL-E177R) [
15], B6.129-Gt (ROSA)26Sortm1(cre/ERT2)Tyj/J (CreER
T2) [
22], B6.Cg-Tg (IghMyc)22Bri/J (EμMyc) [
48], and B6.129-Trp53 < tm1Brd>/TacThst (p53KO) [
49]. In transplantation experiments, F1 hybrids of C57BL/6 J (B6) and 129S1/SvImJ (129) or B6(Cg)-Tyrc-2 J/J (B6 albino) and 129X1/SvJ (129 albino) were used as recipients. Generation of the leukemia and lymphoma, monitoring of disease development by bioluminescence imaging (BLI) and therapy were performed as described earlier [
50].
For the AML model with Cre-inducible expression of p53
E177R, double-heterozygous
Trp53LSL-E177R/+; Rosa26
CreERT2/+ mice were intercrossed. Fetal liver cells from
Trp53LSL-E177R/LSL-E177R; Rosa26
CreERT2 embryos (E14–16) were isolated, transduced with retroviruses expressing the
AML1/ETO9a fusion oncogene (co-expressed with GFP) and
NrasG12D oncogene (co-expressed with firefly luciferase) and 10
6 cells were transplanted into 129 albino recipients as described [
46,
50]. Recipients were lethally irradiated (7 Gy) 24 h before transplantation using the X-RAD 320iX system. Recipients were provided with neomycin-supplemented water (1.6 g ml
− 1, pH 3) starting 2 days before transplantation until 3 weeks after. For in vivo p53 reactivation, recipient 129 albino/B6 albino F1 hybrid mice were sublethally irradiated and injected i.v. with 10
6 AML cells. Both male and female mice were used as recipients for female AML cells with and without reactivatable p53. Leukemia progression was monitored by BLI: mice were imaged under isoflurane anesthesia 5 min after i.p. injection of 100 μl of D-luciferin solution (15 mg ml
− 1) using an IVIS 100 imaging system (Xenogen).
For the EμMyc lymphoma model, double-heterozygous
Trp53LSL-E177R/+;
Rosa26CreERT2/+ females were bred with EμMyc transgenic males. Lymphomas from EμMyc;
Trp53LSL-E177R/ offspring mice with or without CreER
T2 were used for transplantation into 129/B6 F1 hybrid recipient mice as described [
50]. After disease onset was confirmed by palpation of enlarged mandibular, axillary or subiliac lymph nodes, mice were treated 1 week with daily i.p. injections of 1 mg tamoxifen. Mice were euthanized when pre-defined humane endpoint criteria were reached. Control experiments for Cre-mediated toxicity were performed with EμMyc;
Rosa26CreERT2/+ lymphomas. Both male and female donor and recipient mice were used.
For the spontaneous T-lymphoma model, both male and female
Trp53LSL-E177R/LSL-E177R;
Rosa26CreERT2 mice were examined with magnet-resonance tomography using 7 T Clinscan 70/30 USR (Bruker) as described [
51]. T2 weighted sequences triggered on respiration in transverse and coronal orientation were used for anatomical imaging of the thymus. The total measurement time was approximately 28 min per mouse. Tumor size was measured using RadiAnt DICOM Viewer and tumor volume was calculated with the ellipsoid formula V = 4/3*π*abc.
Trp53LSL/LSL mice without Cre were used as a control cohort. The first imaging was performed at the age of 120 days or earlier for mice that showed clinical symptoms of thymic lymphoma (weight loss, hunchback posture, shortness of breath).
For reactivation of E177R expression via Cre-mediated recombination in vivo, mice were injected i.p. for 7 consecutive days with 100 μl of 10 mg ml− 1 tamoxifen (Sigma) in sterile corn oil. For mock treatment, mice were injected with 100 μl of corn oil only.
Cell culture
For generation of mouse AML cell lines, primary tumors (spleen, bone marrow) were mechanically disrupted by mashing through 70 μm EASYstrainer (Greiner). After erythrocyte lysis (5 min at RT in ACK buffer, Thermo Fisher), cells were collected by centrifugation, resuspended and cultured in B-cell medium (DMEM:IMDM 1:1, Life Technologies), 20% fetal bovine serum (FBS, Sigma-Aldrich), 100 U ml− 1 penicillin/streptomycin (Life technologies), 5 × 10− 5 M 2-mercaptoethanol) supplemented with 0.2 ng ml− 1 murine IL3, 2 ng ml− 1 IL6 and 20 ng ml− 1 SCF (all from Immunotools). Cells were maintained on multi-well plates for suspension cells (Greiner) at ambient oxygen in a humidified cell culture incubator (37 °C with 5% CO2). For colony formation assay, 50,000 cells were plated in MethoCult™ GF M3434 medium (STEMCELL Technologies, 1.5 ml per well on 6-well plate) and colonies were counted after 7 days.
CRISPR-Cas9
For generation of AML cells with CRISPR-mediated p53 knock-out,
Trp53LSL-E177R/LSL-E177R;
Rosa26CreERT2 leukemia cells were transduced with pMSCV-Cas9-Blast retrovirus. For pMSCV-Cas9-Blast plasmid, the puromycin resistance (
pac) gene in the pMSCV-Cas9-Puro plasmid (RRID: Addgene_65655) was replaced with the blasticidin-S resistance gene (
bsr) PCR-amplified from lentiCas9-Blast plasmid (RRID: Addgene_52962) using primer pair 5′-catgcAAGCTTccaccatggccaagcctttgtctcaag and 5′-gatcgATCGATttagccctcccacacataacc using HindIII and ClaI restriction sites, respectively. MSCV-Cas9-Blast retrovirus was packaged using Platinum-E cells as described [
51] and used for spin-infection in B-cell medium supplemented with 6 μg ml
− 1 polybrene (Sigma). AML cells were spin-infected 4 times (600×g, 40 min) in 24-well tissue culture plates (Greiner) coated with 40 μg ml
− 1 RetroNectin (Takara). After 1 week of selection with 50 μg ml
− 1 Blasticidin S (Invivogen), 5000 cells were plated on 35 mm tissue culture dish (Greiner) in MethoCult™ GF M3434 medium and grown for 2 weeks. Single colonies were picked, expanded and screened for Cas9 expression by Western blotting. One validated single cell clone (AML-Cas9) was used for CRISPR editing. Oligos, encoding control (scrambled) sgRNA (sense 5′-caccgaaatgtgagatcagagtaat-3′, antisense 5′-aaacattactctgatctcacatttc-3′) or sgRNA targeting
Trp53 locus [
50], were cloned into lentiviral SGL40C.EFS.RFP657 vector (gift from Dirk Heckl, RRID:Addgene_69147 [
52]) via BsmBI site using Golden Gate cloning. Lentiviruses were produced in HEK293-T cells and used for infection of the AML-Cas9 cell clone [
20]. Infection efficiency was analyzed by flow cytometry for RFP 48 h after infection and the pool of cells was directly used for transplantation. CRISPR-mediated
Trp53 knock-out was confirmed by Sanger sequencing and InDel analysis using the TIDE algorithm [
53].
Flow cytometry
Immunophenotyping and analysis of differentiation of leukemia cells was performed as described [
50] on an Accuri C6 Plus flow cytometer (BD Biosciences) with the following antibodies: mouse Gr1-PE (Milteny Biotec #130–102-426, RRID: AB_2659861), mouse CD11b-APC (Milteny Biotec #130–091-241, RRID: AB_244268), mouse Ly-6A/E (Sca-1)-PE/Cy5 (BioLegend #108109, RRID: AB_313346), mouse CD117 (c-kit)-PE (BioLegend #105807, RRID: AB_313217), Rat IgG2a, κ Isotype Ctrl-PE/Cy5 (BioLegend #400509), Rat IgG2b, κ Isotype Ctrl-PE (BioLegend #400607; RRID: AB_326551). BrdU labeling of S-phase cells and flow cytometry analysis were done using A488-conjugated anti-BrdU antibodies (BD Biosciences #347580, RRID: AB_400326) as described [
50]. For apoptosis assay, Annexin V-APC (MabTag) or CaspGLOW™ Red Active Caspase-3 Staining Kit (Biovision) kits were used according to the manufacturer’s protocols.
Immunohistochemistry and western blot
Immunoblotting (WB) was performed as described [
15]. Cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 2% NP-40, pH 8.0) supplemented with protease inhibitor (cOmplete ULTRA tablets EASYpack, Roche) and phosphatase inhibitor (PhosSTOP, Roche). For WB the following antibodies were used: anti-p53 (NCL-p53–505, Leica Microsystems, 1:2000, RRID: AB_563932), anti-p21 (F-5, #sc-6246, Santa-Cruz, 1:200, RRID: AB_628073), anti-Cas9 (E7M1H, #19526, Cell Signaling, 1:1000, RRID: AB_2798820), anti-β-actin (AC-15, #ab6276, Abcam, 1:10000, RRID: AB_2223210). Secondary anti-mouse or anti-rabbit IgG-HRP (GE Healthcare, 1:5000) and SuperSignal ECL kit (Thermo Fisher) were used for detection. Tissue samples for histology and immunohistochemistry (IHC) were formalin-fixed and processed as described before [
15]. For IHC the following antibodies and kits were used: anti-cleaved caspase-3 (#9661, Cell Signaling, 1:100, RRID: AB_2341188), DeadEnd TM colorimetric TUNEL System (Promega), anti-p53 (NCL-p53–505, Leica Microsystems, 1:1000, RRID: AB_563932), anti-GFP (ab6556, Abcam, 1:500, RRID: AB_305564), anti-BrdU (BU1/75(ICR1), #OBT0030G, Bio-Rad, 1:100, RRID: AB_609567) and biotinylated rabbit anti-mouse IgG (31,834, Invitrogen, 1:500). Detection of senescence-associated β-galactosidase activity (SA-βGal) in frozen tissue sections and in cytospin samples was performed as described [
15,
50]. Images were acquired using the Leica Aperio Versa slide scanner and Leica Aperio eSlide Manager software v. 1.0.3.37. Aperio ImageScope software v. 12.3.2.8013 was used for IHC image analysis, quantification was performed using Positive Pixel Count Algorithm v.9 and calculated as the ratio N
positive/N
total pixels in 10 fields of view (1000X1000 pixel each) per sample relative to the mean of the untreated samples as baseline.
PCR and RT-PCR
PCR detection of the LSL cassette and Cre-mediated recombination in the targeted
Trp53 allele was done as described [
15]. For reverse-transcription real-time PCR (RT-qPCR) RNA was isolated from cells or tissue samples using the RNeasy Mini Kit (Qiagen) and cDNA was generated with the SuperScript VILO cDNA Synthesis Kit (Invitrogen). Gene expression was analyzed on a LightCycler 480 (Roche) using SYBR Green (Thermo Fisher Scientific) and primers specific for mouse
Trp53,
Cdkn1a/p21,
Ccng1,
Bbc3/Puma,
β-Actin/Actb [
50]. Data were evaluated by the ΔΔCt method using β-actin gene expression for normalization.
Chromatin immunoprecipitation (ChIP)
AML cells were treated and fixed after 48 h with freshly prepared 18.5% (w/v) paraformaldehyde (PFA) for 10 min at RT, aiming at a final concentration of 0.88% (v/v) PFA. Crosslinking of DNA and proteins was terminated by quenching unreacted PFA by addition of glycine to 125 mM end concentration and further incubation for 5 min at RT. Cells were pelleted by centrifugation at 300 x g for 10 min at 4 °C, washed twice with ice-cold PBS and lysed at a concentration of 2 × 107 cells ml− 1 in SDS lysis buffer containing protease inhibitor. 250 μl lysate per tube was sonicated to shear DNA to a fragment size of 200–1000 bp, using the Sonicator Bioruptor Twin UCD-400 (Diagenode) for 5 cycles of 30 s ON/ 30 s OFF. After sonication, cell debris was pelleted by centrifugation for 10 min at 10,000 x g at 20 °C. Supernatant containing the sheared chromatin was aliquoted á 100 μl and either frozen at − 80 °C for later use or directly processed. For each antibody, one 100 μl aliquot was used and diluted 1:10 with dilution buffer. Pre-clearing was performed for 1 h at 4 °C using 50 μl blocked Protein G-coupled Sepharose beads (GE Healthcare, 1:1 slurry with 20% EtOH) per sample. Supernatant of pelleted beads (3000 x g, 1 min, 4 °C) was transferred into a new tube and 1% was removed as input DNA and stored at 4 °C. Samples were rotated over night at 4 °C with 2.5 μg antibody: p53 (FL393, Santa Cruz sc-6243) or isotype control (E5Y6Q, Cell Signaling #61656). For precipitation, protein-DNA complexes were bound to blocked beads (50 μl per sample) for 4 h at 4 °C. Beads were washed once with each Low Salt, High Salt and LiCl Immune Complex washing buffers and twice with TE buffer. Crosslinking was reverted by incubating immunoprecipitated samples and inputs at 99 °C for 10 min with 100 μl of 10% (w/v) Chelex 100 solution. Proteins were digested with proteinase K for 30 min at 55 °C and this enzyme was subsequently inactivated at 99 °C for 10 min. DNA was eluted in two steps with ddH2O, first with 55 μl and then with 100 μl each time by centrifugation (1 min at 12,000 x g). Analysis of bound DNA fragments were performed using qPCR with 1 μl DNA per reaction using primers specific for p53 response elements in the Cdkn1a/p21, Bax and Bbc3/Puma genes.
Statistical analysis
For statistical analysis the GraphPad Prism 8 software was used. Graphs show mean values obtained with n technical or biological replicates, and error bars in all figures represent standard deviation (SD), unless indicated otherwise. Two groups were tested for statistically significant differences by a two-sided unpaired t-test or, if not normally distributed, by a Mann-Whitney test. Multiple groups were tested by 1way ANOVA in conjunction with a Dunnett’s multiple comparisons test. P-values of 1way ANOVA and selected pairwise comparisons are reported in the respective figures. Three or more groups that have been split on two independent variables (here treatment and genotype) were analyzed by 2way ANOVA in conjunction with Sidak’s multiple comparisons test. P-values for the interaction effect between the two independent variables and P-values of selected pairwise comparisons are reported in the figures. Survival data were analyzed with pairwise Log-rank (Mantel-Cox) tests. A p-value < 0.05 was used as level of significance.
Discussion
Previous studies have indicated that many p53-deficient tumors regress when p53 is restored, implying that they are strongly addicted to the absence of p53 activity [
19‐
22,
24]. However, it has remained unclear how much p53 activity is required to trigger tumor regression [
18]. Given the yet limited pharmacological abilities to fully reactivate a p53 mutant [
25,
26], we aimed to analyze whether partial p53 reactivation may suffice to induce a therapeutic effect. To reproducibly reactivate p53 to a defined suboptimal degree, we chose to genetically limit p53 activity using the previously well-characterized partial LOF variant E177R [
15]. This mutation does not affect any DNA contacting residues and maintains a normally folded DNA binding domain [
41]. Nevertheless, it is impaired in DNA binding because it fails to form a strong intermolecular salt-bridge which is crucial to stabilize the tetrameric protein complex on DNA [
43]. Previous DNA binding studies in vitro and in vivo have characterized the DNA binding defect as a global reduction in DNA binding across the entire target gene spectrum [
44,
45]. By limiting global DNA binding in a genetically fixed manner, the E177R mutation is suitable to model the consequences of an incompletely reactivated p53 mutant.
Even though the E177R mutation reduced DNA binding globally, we observed transactivation of the typical p53 target genes (Fig.
1e) and induction of a broad range of effector programs including cell cycle arrest, senescence, differentiation and apoptosis (Fig.
2). While transactivation of antiproliferative target genes like
p21/Cdkn1a is in line with the described phenotype of E177R knock-in mice and explains induction of cell cycle arrest, senescence and differentiation [
15], activation pro-apoptotic target genes was rather unexpected, because E177R and several other related cooperativity mutants are generally characterized by an apoptosis defect [
43,
57‐
59]. However, the ability of p53 to induce apoptosis is highly context-dependent and modulated by the extent and dynamics of p53 protein accumulation as well as the intrinsic apoptosis threshold of the cell and its level of mitochondrial priming [
60‐
64]. It is therefore conceivable that sustained high-level expression of a DNA-binding impaired p53 mutant can trigger apoptosis especially in cell types with an intrinsically low apoptosis threshold [
65,
66]. In line, massive constitutive stabilization of the E177R mutant protein by knockout of Mdm2 was shown to trigger lethal apoptosis in highly proliferative embryonic tissues [
65], which have a lower apoptosis threshold than most adult tissues due to Myc-mediated mitochondrial priming [
65,
66]. Similarly, tumors in E177R mice commonly display constitutive stabilization of the E177R mutant protein, and DNA damage in such tumors was reported to induce pro-apoptotic p53 target genes and render them sensitive to chemotherapy [
47]. In all our leukemia and lymphoma models, the E177R protein was readily detectable by immunohistochemistry (Figs.
3e,
4a,
5f), showing a staining pattern similar to human tumors with a massively stabilized mutant p53 protein. Moreover, p53-deficient leukemias and lymphomas commonly upregulate p19Arf [
20,
47], which can sequester Mdm2, thereby contribute to the massive E177R accumulation, overcome the apoptosis-deficiency and enable tumor cell killing by E177R.
In vivo, additional non-cell-autonomous p53 effects might contribute to eradication of tumor cells [
21,
67,
68]. In liver carcinomas, for example, wild-type p53 restoration triggers infiltration by innate immune cells like macrophages, neutrophils and lymphocytes that support clearance of senescent tumor cells [
21]. While we have not detected changes in macrophages, we have observed lymphocytic infiltration upon E177R activation (Fig.
4), which makes it tempting to speculate that immune infiltration induced by p53 in a non-cell-autonomous manner might contribute to tumor regression in vivo. In summary, the presented data indicate that E177R is directly capable of inducing apoptosis in p53-deficient leukemia and lymphoma cells and provide an explanation for the observed cancer regression. Whether and how immune cells contribute remains to be investigated.
We observed cancer regression not only in AML but also in lymphoma models, including thymic T cell lymphomas that spontaneously develop in p53-deficient mice. While non-reactivated mice mostly succumbed to thymic lymphoma, reactivated mice at the time of sacrifice more often presented with other types of cancer, often sarcomas (Fig.
6e and f), suggesting that lymphomas are more vulnerable to p53 reactivation than other cancer entities. A differential sensitivity of sarcomas and lymphomas was also reported upon restoration of wild-type p53, where restoration in lymphomas caused widespread apoptosis, whereas sarcomas showed a delayed anti-proliferative response with features of senescence [
22]. The higher sensitivity of hematopoietic cancers is not entirely unexpected as already the normal bone marrow displays an exquisite vulnerability to elevated p53 activity which is at least partially explained by mitochondrial priming of the hematopoietic compartment [
61,
66,
69‐
72]. Moreover, this is in line with clinical studies on p53/mutp53-reactivating compounds like Mdm2-inhibitors or eprenetapopt (APR-246), which have reported clinical responses mostly in patients with hematological cancers [
37,
38,
73].
Even though most animals demonstrated strong responses to partial reactivation, none of the animals was cured and all relapsed eventually. The cause of relapse differed between the different models. Relapsed EμMyc-driven lymphomas showed a high percentage of p53-negative tumor cells (Fig.
5c), suggesting that not all lymphoma cells had recombined the LSL-E177R allele and therefore escaped due to a technically inefficient reactivation. An alternative explanation would be a secondary loss or inactivation of the E177R mutant, for example, by LOH. In contrast, relapsed AML mice showed homogeneous high-level expression of the E177R mutant, indicating that some tumor cells eventually adapt and tolerate E177R expression. Of note, these observations are not unique to partial p53 reactivation and similar findings have been reported in the previous studies with wild-type p53 restoration. All EμMyc lymphomas with tamoxifen-inducible p53ER
TAM activity relapsed after reactivation, losing either p53ER
TAM expression or deleting its upstream activator p19ARF [
19]. Responses to partial reactivation are therefore mostly transient, calling for synergistic approaches such as DNA damaging chemotherapeutics that might help to boost p53 activity to obtain longer-lasting remissions. In AML, even a transient response might be efficient, by inducing the clinical remission needed for a bone marrow transplant as the final curative treatment.
Tamoxifen, used to induce E177R-mediated tumor regression in our study, is an estrogen receptor (ER) antagonist. As estrogens vary between sexes and interfere with the p53 pathway [
74], the anti-estrogenic tamoxifen activity might have contributed to the p53 reactivation response in a sex-dependent manner. In the AML model, both the LSL and KO leukemia cells were derived from female embryos and 86% of all recipient mice were also female. The improvement in survival upon tamoxifen treatment of LSL-E177R AML mice remained highly significant when excluding male mice from the survival analysis (Supplemental Fig. S
3). A gender-effect as the cause for the differential in vitro and in vivo response to tamoxifen treatment can therefore be excluded. However, due to the small number of male recipient mice, we could not analyze whether the reactivation response is different in male AML mice. Both lymphoma models comprised comparable numbers of male and female mice and the reactivation responses were similar in both sexes (Supplemental Fig. S
1 and S
2). In the transplanted Myc lymphomas, reactivation was also independent of the sex of the lymphoma donor (Supplemental Fig. S
1). Together, these analyses indicate no confounding sex-dependent effects in the hematopoietic cancer models studied here. This is in line with the clinical use of tamoxifen primarily for the treatment of hormone-dependent ER+ breast and endometrial cancer. In other ER-negative cancer types, anti-tumor effects of tamoxifen require doses 4–8 fold higher than necessary for ER inhibition [
75], suggesting that these effects are hormone-independent.
Of note, tumor cells can not only become addicted to the loss of wild-type p53 activity, they can also become dependent on neomorphic GOF properties of the p53 mutant. Refolding a GOF mutant would therefore not only restore some degree of wild-type function but simultaneously deprive tumor cells of survival-promoting GOF effects. As such, it has been demonstrated that loss of GOF activities by therapeutic ablation of the mutant protein can be sufficient to induce cancer regression, even in the absence of any restoration of wild-type function [
76,
77]. By switching p53-null tumor cells to E177R, we can exclude that the responses observed in our cancer models are mediated by a loss of GOF properties. However, it is reasonable to assume that an additional loss of GOF would synergize with restoration of wild-type function and could further enhance the extent and duration of tumor regression. It is therefore expected that a partial p53 reactivation would be even more effective in tumors bearing GOF missense mutants rather than pure LOF mutants.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.